Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on…
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., (approved for listing on NYSE American under “CLDI”), a clinical-stage…
Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
FOR IMMEDIATE RELEASE July 18, 2023 LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)– City of…
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium…
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from the transaction, before payment of transaction expenses, expected to be up…
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs
Calidi was awarded $3.1 million to support the development of Supernova-1 (SNV1) program through IND…